CHO Pharma

CHO Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of CHO Pharma (6586.TWO) as of Oct 31, 2026 is 100.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 105.02 % — a change of -4.36% (lower).

FCF Conversion

100.44 %

YoY

-4.36%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of CHO Pharma is 2025 100.44 % . FCF Conversion Rate (FCF/EBITDA) of CHO Pharma was 2024 105.02 % . It decreases by -4.36% lower compared to the previous year.

The CHO Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
80.74 TWD
Jan 1, 2019
77.62 TWD
Jan 1, 2020
91.26 TWD
Jan 1, 2021
95.23 TWD
Jan 1, 2022
76.51 TWD
Jan 1, 2023
95.77 TWD
Jan 1, 2024
105.02 TWD
Jan 1, 2025
100.44 TWD
The CHO Pharma FCF Conversion history
YEARFCF ConversionYoY
100.44 %-4.36%
105.02 %+9.66%
95.77 %+25.17%
76.51 %-19.66%
95.23 %+4.36%
91.26 %+17.58%
77.62 %-3.87%
80.74 %-2.58%
82.88 %+11.82%
74.12 %-41.64%
127.01 %+7.06%
118.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CHO Pharma Stock analysis

What does CHO Pharma do? CHO Pharma, Inc. develops and commercializes innovative biopharmaceutical products using proprietary glycan engineering technologies. The company focuses on eight technology categories: homogeneous antibody drugs, monoclonal antibodies for cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, Saccharin tablets, sugar probes, sugar molecular synthesis and identification, and derivative patents of innovation development plans. These products are targeted at medical and pharmaceutical markets requiring advanced therapeutic solutions. The company's revenue streams come from the development and commercialization of these specialized biopharmaceutical products. Its primary customers are healthcare providers, hospitals, and pharmaceutical distributors seeking advanced treatments for cancer, immune disorders, and infectious diseases. The company's technology segments include antibody therapies, vaccine development, and antiviral drug applications, all leveraging its glycan engineering platform. CHO Pharma's business model centers on leveraging its patented glycan engineering technologies to create and sell high-value pharmaceutical products. The company's product portfolio spans multiple therapeutic areas, including oncology, immunology, and virology, with a focus on developing innovative treatments that address unmet medical needs. Its commercialization strategy involves direct sales to healthcare institutions and partnerships with pharmaceutical distributors for broader market reach. CHO Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CHO Pharma stock

FCF Conversion Rate (FCF/EBITDA) of CHO Pharma is 100.44 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of CHO Pharma changed from 105.02 % to 100.44 %, representing a -4.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) CHO Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s CHO Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CHO Pharma

All Key Metrics — CHO Pharma